NYSE:DHRLife Sciences
Assessing Danaher (DHR) Valuation After A Steep Share Price Pullback
Why Danaher (DHR) is Drawing Investor Attention Now
Danaher (DHR) is back on investor radars after a period of weaker share performance, with the stock down about 14% over the past year and roughly 28% lower year to date.
Those moves are prompting closer scrutiny of how the company’s US$24.8b revenue base and US$3.7b in net income, spread across Biotechnology, Life Sciences and Diagnostics, stack up against its current US$116b market value.
See our latest analysis for Danaher.
Recent trading...